Dapagliflozin, on the other hand, suggested a possible trend toward lowering the incidence of respiratory system malignancies, while statistical significance remained elusive.
← all excerpts
Relationship between SGLT2 inhibitor use and specific cancer types: a systematic review and meta-analysis.
2
—
—
The sentences
Canagliflozin was associated with a potential 14% reduction in respiratory cancer risk (RR: 0.86, 95% CI: 0.54, 1.38; I2 = 0%), while Empagliflozin showed a trend toward an increased risk compared with placebo (RR: 1.33, 95% CI: 0.70, 2.51; I2 = 0%).